Okumura T, Taylor I L, Fukagawa K, Tso P, Pappas T N
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Brain Res. 1995 Feb 27;673(1):153-6. doi: 10.1016/0006-8993(94)01432-h.
We have recently reported that apolipoprotein A-IV (apo A-IV), a protein associated with lipoproteins, acts in the brain to inhibit gastric acid secretion. In the present study, we determined whether or not apo A-IV has an anti-ulcer action via the central nervous system using Sprague-Dawley rats. Intracisternal injection of apo A-IV dose-dependently (2.0-4.0 micrograms/rat) reduced the severity of gastric mucosal lesions induced by intravenous injection of 2-deoxy-D-glucose or subcutaneous administration of indomethacine. A higher dose (15 micrograms) of apo A-IV injected intraperitoneally failed to inhibit the development of gastric mucosal damage evoked by these ulcerogenic agents. These results suggest for the first time that apo A-IV has an anti-ulcer action through a central mechanism.
我们最近报道,载脂蛋白A-IV(apo A-IV)是一种与脂蛋白相关的蛋白质,在大脑中发挥作用以抑制胃酸分泌。在本研究中,我们使用Sprague-Dawley大鼠确定apo A-IV是否通过中枢神经系统具有抗溃疡作用。脑池内注射apo A-IV剂量依赖性地(2.0 - 4.0微克/大鼠)减轻了静脉注射2-脱氧-D-葡萄糖或皮下给予吲哚美辛所诱导的胃黏膜损伤的严重程度。腹腔内注射更高剂量(15微克)的apo A-IV未能抑制这些致溃疡剂引起的胃黏膜损伤的发展。这些结果首次表明apo A-IV通过中枢机制具有抗溃疡作用。